A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex...

Area of Science:

• Rheumatology
• Immunology
• Biomarker Discovery

Background:

• Rheumatoid arthritis (RA) treatment response varies significantly among patients.
• Identifying predictors for biological agent efficacy is crucial for personalized medicine.
• MRP8/14 serum levels have shown promise in predicting response to biological therapies in RA.

Purpose of the Study:

• To develop a treatment algorithm for rheumatoid arthritis (RA).
• To utilize MRP8/14 serum levels and clinical parameters for predicting response to biological agents.
• To personalize treatment selection for RA patients initiating biological therapies.

Main Methods:

• Measured baseline serum MRP8/14 levels in 170 RA patients starting infliximab, adalimumab, or rituximab.
• Developed a predictive score using logistic regression, incorporating MRP8/14 levels and clinical variables.
• Created a treatment algorithm categorizing expected response (high, intermediate, low) per drug type.

Main Results:

• Higher MRP8/14 levels and DAS28 scores predicted increased response probability.
• Rheumatoid factor positivity, higher HAQ, and prior TNF-inhibitor use decreased response probability.
• The algorithm recommended specific treatments for subgroups, showing good prediction accuracy and potential for improved group response rates.

Conclusions:

• MRP8/14 levels combined with clinical predictors can personalize RA biological treatment.
• This predictive approach may enhance cost-effectiveness in managing RA.
• The developed algorithm offers a tool for optimizing biological therapy selection in RA patients.